Vycor Medical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 10, 2022 at 08:00 am EDT
Share
Vycor Medical, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was USD 0.313833 million compared to USD 0.295749 million a year ago. Net loss was USD 0.074552 million compared to USD 0.242919 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. Basic loss per share was USD 0.01 compared to USD 0.01 a year ago.
Vycor Medical, Inc. provides surgical and therapeutic solutions. The Company designs, develops and markets neurological medical devices and therapies. The Company operates through two segments: Vycor Medical and NovaVision. The Vycor Medical segment designs, develops and markets medical devices for use in neurosurgery. The NovaVision segment provides non-invasive rehabilitation therapies for those who have vision disorders resulting from neurological brain damage such as that caused by a stroke. Vycor Medical's product Vycor Medical's ViewSite Brain Access System (VBAS) is a next generation retraction and access system. Vycor Medical focuses on brain and cervical surgical access systems for sale to hospitals and medical professionals. NovaVision's products include Vision Restoration Therapy (VRT), NeuroEyeCoach and Neuro-Eye Therapy (NeEt). The Company operates in the United States and Europe.
VYCOR MEDICAL, INC. 
